GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
SMS Pharmaceuticals Ltd

SMS Pharma: Income tax demand slashed to Rs. 40.28 Lakhs from Rs. 7.19 Crores

REGULATORY ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 29 Apr 2026, 12:03 PM IST  ·  BSE ID: e5718213-483a-4966-9889-518a4431345b
View Original BSE Filing (PDF)
💡
In Simple Terms
The income tax department dramatically cut its claim against SMS Pharma from Rs. 7.19 Crores to Rs. 40.28 Lakhs after the company appealed the original demand.
🤖 AI Summary
  • Income tax demand reduced to Rs. 40.28 Lakhs from Rs. 7.19 Crores for FY 2018-19
  • Rectification order received 28 April 2026 under Section 154 of Income Tax Act
  • Assessment Unit had raised demand via Section 147 read with Section 144B for income additions and deduction disallowances
  • Company filed appeal before Commissioner of IT (Appeals) and sought penalty proceedings abeyance
  • Management confirms no material impact on financial, operational, or other activities at this stage
🔢 Key Numbers — exact figures from BSE filing, not rounded
Rectified tax demand
Rs. 40.28 Lakhs
Original tax demand
Rs. 7.19 Crores
Reduction in demand
Rs. 6.78 Crores 72 Lakhs (94.4% decrease)
Assessment year
2018-19
Rectification order date
28 April 2026
🏢 How This Affects the Company
💰
Financial Impact
Reduction from Rs. 7.19 Crores to Rs. 40.28 Lakhs eliminates approximately Rs. 6.79 Crores in disputed tax exposure. Management states no material impact on financials at current stage, but appeal outcome and penalty proceedings remain outstanding.
⚠️
Risk Impact
Ongoing appeal and separate penalty proceedings under Section 270A create residual tax and litigation risk. Rectification order acceptance or further dispute will affect final liability, but magnitude is now substantially reduced.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required. Monitor BSE filings for updates on appeal outcome and penalty proceedings resolution.
👤
Who Is Affected
All shareholders. Potential liability reduction from Rs. 7.19 Crores to Rs. 40.28 Lakhs benefits equity base, but residual exposure from pending appeal and penalty proceedings affects retained earnings until final resolution.
🔍
Management Signal
Proactive rectification application and appeal filing demonstrate engagement with tax authorities; management confidence in substantially reducing original demand, though outcome remains subject to appellate process.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Commissioner of IT (Appeals) order on pending appeal — outcome will determine final tax liability for FY 2018-19
Penalty assessment outcome under Section 270A — filing should disclose quantum when penalty proceedings concluded
Further rectification or appellate order — monitor for any subsequent communication from Income Tax Department
MEDIUM RISK Rectified demand substantially reduced, but appeal and penalty proceedings remain unresolved. Final liability outcome uncertain pending appellate and penalty adjudication.
💡 Investor Takeaway
SMS Pharma secured a rectification order reducing FY 2018-19 income tax demand to Rs. 40.28 Lakhs from Rs. 7.19 Crores. Appeal to Commissioner of IT (Appeals) is ongoing, and separate penalty proceedings remain active. Management confirms no material current impact on financials.
⚖️ Strengths & Concerns

✅ Positives

  • Rectification order confirms 94.4% reduction in original tax demand, from Rs. 7.19 Crores to Rs. 40.28 Lakhs
  • Company secured abeyance of penalty proceedings pending appeal, deferring potential additional monetary exposure

⚠️ Concerns

  • Appeal before Commissioner of IT (Appeals) remains pending; final liability unresolved pending appellate outcome
  • Separate penalty proceedings under Section 270A initiated for under reporting of income; quantum not quantified in filing
📅 Company Track Record
SMS Pharmaceuticals received income tax demand notice on 31 March 2026 (Reg 30 disclosure) for Rs. 7.19 Crores against FY 2018-19. Assessment order passed under Section 147 read with Section 144B citing income additions and disallowance of deductions under Section 35. Company filed rectification application under Section 154; order received 28 April 2026 reducing demand to Rs. 40.28 Lakhs.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.